Skip to NavigationSkip to content

FDA approves first treatment for peanut allergy

Published on 03/02/20 at 09:53am

The FDA has approved its first treatment for peanut allergy in patients between ages four and 17.

The drug is Aimmune Therapeutics Inc’s Palforzia, or AR101, and patients must take a daily dose to protect themselves from accidental exposure to peanuts. Its reported list price will be $890 a month. Daniel Adelman, the Chief Medical Officer of Aimmune, said: “Not only is PALFORZIA the first approved therapy for peanut allergy, but it is the first approved therapy for any food allergy.”

The treatment works through specific allergenic proteins that are ingested initially in very small quantities, followed by incrementally increasing amounts. This results in the ability to mitigate allergic reactions over time. The new drug's doses contain the equivalent of small amounts of peanuts. 

However, the Aimmune Therapeutics Inc warned that the new drug can cause life threatening anaphylaxis, and due to this it will only be available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).

Peanut allergy is one of the most common food allergies in the world. It affects more than 1.8 million children and teens in the United States and between 1997 and 2008 the number of people allergic tripled.

Conor Kavanagh


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches